Latest news
Categories
News archive
Publication on Empty Particles for the Treatment of ALS
26 November, 2020
The publication “Empty mesoporous silica particles significantly delay disease progression and extend survival in a mouse model of ALS” has been published in Nature Research Scientific Reports, Nov 26, 2020. The publication relates to Nanologica’s patent application “Porous particles for use in treatment, prevention and/or postponement of degeneration of neurons and glia” that became public on Oct. 15, and demonstrates how empty porous silica particles has the potential of delaying the disease progression and extending
Nanologica presents on Erik Penser Bank Company Day
25 November, 2020
Today at approximately 15.20, CEO Andreas Bhagwani will present Nanologica at Erik Penser Bank Company Day. The presentation can be followed live here. For more information and schedule of presenting companies, please visit Erik Penser Bank.
Biotechgate Digital Partnering Nov 23-26
23 November, 2020
Nov 23-26, Nanologica will take part of the Biotechgate Digital Partnering event. This is a virtual business development event during four days with the aim of partnering and establishing new global connections. The Biotechgate Digital Partnering is designed to support the business development of Biotech, Medtech and Pharma companies through pre-booked one-on-one meetings.
Uppdatering gällande Nanologicas kliniska studie med läkemedelskandidaten NIC-001
18 November, 2020
Starten av Nanologicas kliniska studie med läkemedelskandidaten NIC-001 har flyttats fram ytterligare med anledning av COVID-19. Studien beräknas kunna starta tidigast efter sommaren 2021. Den kliniska studie som avsågs starta under årets tredje kvartal har flyttats fram ytterligare med anledning av COVID-19. Den fortsatta situationen med COVID-19 gör att det under rådande omständigheter är svårt att genomföra kliniska studier som tar sjukvårdsresurser i anspråk och som kräver att försökspersoner besöker sjukhusmiljö. Studien beräknas kunna starta